Having settled its international headquarters in Boudry in 2005, Celgene employs over 800 people in production, research and development and administrative functions in the canton. Construction having begun two years ago, the new Couvet-based production site will allow the company to increase the worldwide supply of its medicines for the treatment of rare types of blood cancers and immuno-inflammatory diseases. This new site will also offer training programs for engineering students.
Celgene’s executives have praised the quality of the relationship the company entertains with the canton, highlighting the efficiency with which this new project materialized. Over the years, the pharma industry has become as important as the watchmaking industry in the canton of Neuchâtel, with close to 10 billion Swiss francs in exports in 2016.
Celgene is an American global biopharmaceutical company based in Summit, New York, employing over 7,000 people worldwide and focusing on the discovery, development and commercialization of medicines for the treatment of cancer and inflammatory disorders.